Brexpiprazole

CHEMBL2105760 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

433.6 g/mol

LogP

4.7

Phase

4

An atypical antipsychotic used as an adjunct treatment for major depressive disorder and for schizophrenia, and also approved for agitation associated with Alzheimer's dementia. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonizes serotonin 5-HT2A receptors. It is taken once daily and generally has a favorable tolerability profile.

Molekularmasse

433,6000 g/mol

LogP

4,70

TPSA

73,10 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Alzheimer's Disease Schizophrenia Generalized Anxiety Disorder Stroke Major Depressive Disorder

Wirkmechanismus

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1

InChI

InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)

Molecular Formula

C25H27N3O2S

HBD / HBA

1 / 5

Rotierbare Bindungen

7

Schwere Atome

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

An atypical antipsychotic used as an adjunct treatment for major depressive disorder and for schizophrenia, and also approved for agitation associated with Alzheimer's dementia. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonizes serotonin 5-HT2A receptors. It is taken once daily and generally has a favorable tolerability profile.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Brexpiprazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105760. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11978813. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Brexpiprazole auf PillFYI

Struktur

Schnelldaten

Formel: C25H27N3O2S
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.